Skip to main content

Table 1 Summary of sample and patient characteristics

From: HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study

  

All samplesa

Archived DNA

Frozen tissue

FFPE tissue

Cervical samplesb

128

(incl. 7 frozen-FFPE and 3 DNA-frozen tumor-tumor pairs)

28

44

(incl. 4 tumor-normal pairs)

56

(incl. 2 tumor-tumor pairs)

Additional samples

7

6 (prostate)

0

1 (vaginal tissue)

Samples with L1 amplicon sequencing

135

34

44

57

Number of samples with QC array data

70

26

44

0

Collection year (Mean ± SD)

1999 ± 11

Not reported

1995 ± 11

2003 ± 9

Age (Mean ± SD)

51.4 ± 14.9

Not reported

51.6 ± 15.5

50.83 ± 14.7

Histological

subtype

Adenocarcinoma (AC)

25

3

9

13

Adenosquamous Carcinoma (ASC)

6

1

0

5

Squamous Cell Carcinoma (SSC)

87

23

27

37

Other

3

1

1

1

Not reported/ not applicable

14

6

7

1

Reported racec

Asian

11

Not reported

1

10

Black

4

2

2

Other

4

2

2

White/caucasian

70

27

43

ADMIXTURE-predicted super-population assignmentd

African (AFR)

4

0

4

Not processed

Admixed

American (AMR)

23

3

20

East Asian (EAS)

4

2

2

European (EUR)

27

16

11

South Asian (SAS)

0

0

0

AMR/EUR

7

1

6

AFR/EUR

1

1

0

SAS/EUR

1

0

1

  1. aData shown for all samples are the sum of or summarize data only from samples for which each characteristic was reported (or estimated)
  2. bIncludes ICC samples, one archived DNA sample from vulval cancer, and one FFPE sample that includes a mix of ICC and endometrial cancer, as well as adjacent normal tissue
  3. cHispanic ethnicity was not reported for any samples
  4. dADMIXTURE-predicted super-population assignments were provided for samples with QC Array call rates > 75%. ADMIXTURE super-populations with contributions of > 20% to a patient’s genome are reported above